Cargando…
A standardized metric to enhance clinical trial design and outcome interpretation in type 1 diabetes
The use of a standardized outcome metric enhances clinical trial interpretation and cross-trial comparison. If a disease course is predictable, comparing modeled predictions with outcome data affords the precision and confidence needed to accelerate precision medicine. We demonstrate this approach i...
Autores principales: | Ylescupidez, Alyssa, Bahnson, Henry T., O’Rourke, Colin, Lord, Sandra, Speake, Cate, Greenbaum, Carla J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10632453/ https://www.ncbi.nlm.nih.gov/pubmed/37940642 http://dx.doi.org/10.1038/s41467-023-42581-z |
Ejemplares similares
-
Response to Comment on So et al. Autoantibody Reversion: Changing Risk Categories in Multiple-Autoantibody–Positive Individuals. Diabetes Care 2020;43:913–917
por: So, Michelle, et al.
Publicado: (2020) -
Early Prognostic Indicators of Subsequent Hospitalization in Patients with Mild COVID-19
por: Ylescupidez, Alyssa, et al.
Publicado: (2021) -
ABCC8-Related Monogenic Diabetes Presenting Like Type 1 Diabetes in an Adolescent
por: Grier, Alexandra E., et al.
Publicado: (2023) -
Systematic Assessment of Immune Marker Variation in Type 1 Diabetes: A Prospective Longitudinal Study
por: Speake, Cate, et al.
Publicado: (2019) -
Insulin is necessary but not sufficient: changing the therapeutic paradigm in type 1 diabetes
por: Lord, Sandra, et al.
Publicado: (2020)